Vitamin D3 and Monocyte Responses in Pregnant Women With Pulmonary Tuberculosis

Brief summary (registry, in English)

This randomized controlled trial evaluated the effects of adjunctive vitamin D3 supplementation on circulating monocyte subsets and the expression of vitamin D receptor (VDR) and interleukin-6 (IL-6) in pregnant women with pulmonary tuberculosis. A total of 32 pregnant women with pulmonary tuberculosis were allocated to receive either standard first-line anti-tuberculosis treatment alone or standard treatment plus oral vitamin D3 supplementation at a dose of 50,000 IU once weekly for eight weeks. Serum 25-hydroxyvitamin D \[25(OH)D\] concentrations, monocyte subset distributions, and monocyte expression of VDR and IL-6 were assessed at baseline, approximately eight weeks after enrollment, and during the early postpartum period. Monocyte subsets were characterized by CD14 and CD16 expression using flow cytometry. The study aimed to investigate whether adjunctive vitamin D3 supplementation modifies vitamin D status and monocyte-related immunological responses in pregnant women receiving treatment for pulmonary tuberculosis.

What you commit to

• Study type: Interventional
• Participants enrolled: 32
• From 1 Dec 2024 to the primary completion date, 1 Dec 2025
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.